Clinical prognostic factors in patients with locally advanced (stage III) nonsmall cell lung cancer treated with hyperfractionated radiation therapy with and without concurrent chemotherapy

Cancer

Volumn 117, Issue 13, 2011, Pages 2995-3003

  Jeremiä, Branislav ^a,b   Miličić, Biljana ^a   Milisavljevic, Slobodan ^a  

^a University Hospital   (Serbia)

^b Institute of Pulmonary Diseases   (Serbia)

Author keywords

chemotherapy; locally advanced nonsmall cell lung cancer; prognostic factors; radiation therapy

Indexed keywords

CARBOPLATIN; ETOPOSIDE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGE; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; KARNOFSKY PERFORMANCE STATUS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS FREE SURVIVAL; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RETROSPECTIVE STUDY; SEX; SURVIVAL; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME;

EID: 79959582432     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25910     Document Type: Article

References (40)

1. Dillman RO, Herndon J, Seagren SL, et al. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst. 1996; 88: 1210-1215. (Pubitemid 26302034)
2. LeChevalier T, Arriagada R, Lacombe-Terrier M-J, et al. Significant effect of adjuvant chemotherapy on survival in locally advanced non-small cell lung carcinoma [letter]. J Natl Cancer Inst. 1992; 84: 58.
3. Sause WT, Kolesar P, Taylor SIV, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer. Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest. 2000; 117: 358-364.
4. Schaake-Konig C, van der Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med. 1992; 326: 524-530.
5. Auperin A, Le Pechoux C, Pignon JP, et al. Concomitant radiochemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. Ann Oncol. 2006; 17: 473-483. (Pubitemid 43329586)
6. Auperin A, Le Pechoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010; 28: 2181-2190.
7. Liang H-Y, Zhou H, Li H-L, et al. Chemo-radiotherapy for advanced non-small cell lung cancer: concurrent or sequential? It's no longer the question: a systematic review. Int J Cancer. 2010; 127: 718-728.
8. Jeremic B, Shibamoto Y, Acimovic L, et al. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol. 1995; 13: 452-458.
9. Jeremic B, Shibamoto Y, Acimovic L, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol. 1996; 14: 1065-1070. (Pubitemid 26105510)
10. Jeremic B, Shibamoto Y, Milicic B, et al. Concurrent radiochemotherapy for patients with stage III non-small cell lung cancer (NSCLC). Long-term results of a phase II study. Int J Radiat Oncol Biol Phys. 1998; 42: 1091-1096. (Pubitemid 29004153)
11. Jeremic B, Shibamoto Y, Acimovic LJ, et al. Hyperfractionated radiation therapy and concurrent low-dose, daily carboplatin/etoposide with or without week-end carboplatin/etoposide chemotherapy in stage III non-small-cell lung cancer: a randomized trial. Int J Radiat Oncol Biol Phys. 2001; 50: 19-25.
12. Jeremic B, Milicic B, Acimovic L, et al. Concurrent hyperfractionated radiotherapy and low-dose daily carboplatin/paclitaxel in patients with stage III non-small cell lung cancer (NSCLC). Long-term results of a phase II study. J Clin Oncol. 2005; 23: 1144-1151. (Pubitemid 46202270)
13. Glatstein E, Makuch RW., Illusion and reality: practical pitfalls in interpreting clinical trials. J Clin Oncol. 1984; 2: 488-497. (Pubitemid 14075983)
14. Simon R., Importance of prognostic factors in cancer clinical trials. Cancer Treat Rep. 1984; 68: 185-192. (Pubitemid 14192170)
15. Curran WJ Jr, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in 3 Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993; 85: 704-710. (Pubitemid 23133591)
16. Feinstein AR., Clinical biostatistics XIV: the purposes of prognostic stratification. Clin Pharmacol Ther. 1972; 13: 285-297.
17. Brundage MD, Feldman-Stewart D, Cosby R, et al. Phase I study of a decision aid for patients with locally advanced non-small cell lung cancer. J Clin Oncol. 2001; 19: 1326-1335. (Pubitemid 32202537)
18. Mackillop MJ., The importance of prognosis in cancer medicine. In:, Gospodarowicz MK, Henson DE, Hutter RBP, et al., eds. Prognostic Factors in Cancer. New York, NY: Wiley & Sons; 2001.
19. Buccheri G, Ferrigno D., Prognostic factors in lung cancer: tables and comments. Eur Respir J. 1994; 7: 1350-1364. (Pubitemid 24235056)
20. Brundage MD, Davies D, Mackillop WJ., Prognostic factors in non-small cell lung cancer: a decade of progress. Chest. 2002; 122: 1037-1057.
21. Watine J., Further comments on "A practical prognostic index for inoperable non-small-cell lung cancer": a clinical biologist's point of view. J Cancer Res Clin Oncol. 1998; 124: 581-583. (Pubitemid 28513122)
22. Jeremic B, Shibamoto Y, Acimovic L, et al. Pre-treatment prognostic factors in patients with stage III non-small cell lung cancer treated with hyperfractionated radiation therapy with or without concurrent chemotherapy. Lung Cancer. 1995; 13: 21-30.
23. Komaki R, Scott CB, Byhardt RW, et al. Failure patterns by prognostic group determined by recursive partitioning analysis (RPA) of 1547 patients on 4 Radiation Therapy Oncology Group (RTOG) studies in inoperable nonsmall-cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 1998; 42: 263-267. (Pubitemid 28502771)
24. Werner-Wasik M, Scott C, Cox JD, et al. Recursive portioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of 5 groups with different survival. Int J Radiat Oncol Biol Phys. 2000; 48: 1475-1482.
25. Socinski MA, Zhang C, Herndon JE II, et al. Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity. Ann Oncol. 2004; 15: 1033-1041. (Pubitemid 39089779)
26. Basaki K, Abe Y, Aoki M, et al. Prognostic factors for survival in stage III non-small-cell lung cancer treated with definitive radiation therapy: impact of tumor volume. Int J Radiat Oncol Biol Phys. 2006; 64: 449-454. (Pubitemid 43083431)
27. Langer C, Hsu C, Curran D, et al. Do elderly patients with locally advanced non-small cell lung cancer benefit from combined modality therapy? A secondary analysis of RTOG 94-10 [abstract]. Int J Radiat Oncol Biol Phys. 2001; 51: 20-21.
28. Machtay M, Seiferheld W, Komaki R, et al. Is prolonged survival possible for patients with supraclavicular node metastasis in non-small cell lung cancer treated with chemoradiotherapy?: Analysis of the Radiation Therapy Oncology Group experience. Int J Radiat Oncol Biol Phys. 1999; 44: 847-853. (Pubitemid 29284134)
29. Edmonson JH, Lagakos SW, Selawry OS, et al. Cyclophosphamide, and CCNU in the treatment of inoperable small cell carcinoma and adenocarcinoma of the lung. Cancer Treat Rep. 1976; 60: 925-932.
30. Stanley KE., Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst. 1980; 65: 25-32. (Pubitemid 10071592)
31. Ball D, Smith J, Wirth A., Failure of T stage to predict survival in patients with non-small-cell lung cancer treated with radiotherapy with or without concomitant chemotherapy. Int J Radiat Oncol Biol Phys. 2002; 54: 1007-1013. (Pubitemid 35292611)
32. Firat S, Byhardt RW, Gore E for the Radiation Therapy Oncology Group. Comorbidity and Karnofsky performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on 4 RTOG studies. Int J Radiat Oncol Biol Phys. 2002; 54: 357-364. (Pubitemid 35286798)
33. Pfister DG, Johnson DH, Azzolli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline. J Clin Oncol. 2004; 22: 330-353. (Pubitemid 41095099)
34. Cox JD, Scott CB, Byhardt RW, et al. Addition of chemotherapy to radiotherapy alters failure patterns by cell type within non-small cell carcinoma of the lung (NSCCL): analysis of Radiation Therapy Oncology Group (RTOG) trials. Int J Radiat Oncol Biol Phys. 1999; 43: 505-509. (Pubitemid 29107167)
35. Jeremic B, Shibamoto Y., Effect of interfraction interval in hyperfractionated radiotherapy with or without concurrent chemotherapy for stage III nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys. 1996; 34: 303-308. (Pubitemid 26031574)
36. Jeremic B, Milicic M, Dagovic A, et al. Interfraction interval in patients with stage III non-small cell lung cancer treated with hyperfractionated radiation therapy with or without concurrent chemotherapy. Final results in 536 patients. Am J Clin Oncol. 2004; 27: 616-625. (Pubitemid 39603278)
37. Werner-Wasik M, Scott C, Graham ML, et al. Interfraction interval does not affect survival of patients with non-small cell lung cancer treated with chemotherapy and/or hyperfractionated radiotherapy: a multivariate analysis of 1076 RTOG patients. Int J Radiat Oncol Biol Phys. 1999; 44: 327-331. (Pubitemid 29205030)
38. Luo J, Margolis KL, Wactawski-Wende J, et al. Association of active and passive smoking mith risk of breast cancer among postmenopausal momen: a prospective cohort study. BMJ. 2011; 342: d1016.
39. Piazza KM, Hyland A,. Prevalence of rules prohibiting home and morkplace smoking correlates mith state-specific breast cancer outcomes: an ecologic analysis [published online ahead of print March 12, 2011]. Tob control.
40. Campling BG, Collins BN, Algazy KM, Scheoll PA, Lam M,. Spontaneous smoking cessation before lung cancer diagnosis. J Thorac Oncot 2011; 6: 517-524.